May 23 (SeeNews) – Bulgarian pharmaceuticals producer Sopharma [BUL:SFA] said that its sales revenue rose by an annual 24% in the first four months of 2023 on the back of an increase in exports.
Revenue from export sales grew by 47% year-on-year in January-April, while sales on the domestic market remained unchanged, Sopharma said in a stock exchange filing on Monday.
In April alone, Sopharma posted a 22% annual decline in sales revenue. The company’s export sales dropped by 31% on the year, whereas domestic sales fell by 5%.
Shares in Sopharma last traded on Monday when they closed at 5.86 levs ($3.24/3 euro) on the Bulgarian Stock Exchange, bourse data show.
Source : SeeNews
